Sentinel node biopsy is not an alternative to axillary dissection in breast cancer

Axillary recurrence after sentinel lymph node biopsy

Sentinel lymph node biopsy (SLNB) without further axillary dissection in patients with sentinel node-negative breast carcinoma appears to be a safe procedure to ensure locoregional control. During a median follow-up of 35 months the false-negative rate was 1% in our study population of 185 patients.

BACKGROUND

The objective of this prospective study is to provide data on follow-up of patients with primary operable breast carcinoma staged with SLNB without axillary lymph node dissection (ALND) if the sentinel lymph nodes (SLNs) were tumour-negative.

METHODS

One hundred and eighty-five patients were enrolled. Preoperative dynamic and static lymphoscintigraphy were performed; both a vital blue dye and a gamma detection probe were used intraoperatively. Patients with tumour-positive SLNs received completion ALND or if no SLNs could be identified. All patients were monitored according to regional follow-up protocols.

RESULTS

The SLNs were identified in 179 out of the 185 patients. In 73 patients the SLNs were tumour-positive and in 106 patients tumour-negative. The median follow-up was 35 months (range 17-59). In one SLN-negative patient an axillary recurrence occurred 26 months after the SLNB (false-negative rate: 1%).

CONCLUSIONS

SLNB without ALND appears to be a safe procedure to ensure locoregional control in SLN-negative breast carcinoma, if carried out by an experienced team.

The Optimal Number of Sentinel Lymph Nodes for Focused Pathologic Examination

The sentinel lymph node (SLN) procedure provides an alternative method for assessing the axillary lymph nodes in patients with breast cancer. The SLN is typically subjected to a focused pathologic examination involving the examination of multiple tissue levels and/or keratin immunohistology. The number of SLNs submitted may vary widely, in some cases rivaling that of a complete axillary dissection (CAD). We examined our experience over the last 2 years in order to determine the optimal number of SLNs for focused pathologic evaluation. All SLN cases for the years 2000 and 2001 were retrieved from the files of the Pathology Department at Magee-Womens Hospital and were tabulated to determine the average number of SLNs per case, the number of SLNs submitted, the actual SLN that was positive for each case, the type of metastasis, and the average number of SLNs per case for each surgeon. There were 662 operative cases that yielded 1576 SLN accessions and 1758 total SLNs. The range of SLNs submitted was 1 to 11. Overall there was a mean of 2.4 SLNs accessioned per case and a mean of 2.7 SLNs per case. A study of the statistics of SLNs submitted by seven surgeons yielded two distinct groups, with one group submitting virtually all of the cases where there were consistently more than four SLNs per case. Ninety-seven percent of positive SLNs were discovered in the first three SLNs submitted, regardless of surgeon identity. The SLNs beyond numbers one to three yielded positive results by keratin in only four cases. Focused pathologic examination of SLNs was most effective for the first three SLNs submitted for any given case. The variation in the number of SLNs submitted per case was different based upon the different practice patterns of surgeons. It is suggested that for more than three SLNs submitted, simple routine lymph node examination would be appropriate.

Outcomes of sentinel node biopsy for breast cancer in British Columbia, 1996 to 2001

BACKGROUND

This study evaluated the outcomes of the first 5 years of sentinel node biopsy (SNB) in British Columbia (BC), Canada, 1996 to 2001.

METHODS

There were 547 SNB procedures for breast cancer performed by 29 surgeons at 12 hospitals in BC between October 1996 and July 2001. Identification, accuracy, and false-negative rates were determined and correlated to patient, tumor, and surgical factors with the chi-square test.

RESULTS

SNB mapping was performed using blue dye alone (15%), radiopharmaceutical alone (6%), or both (79%). A completion axillary dissection was performed in 93%. A median of 2 (range 1 to 16) sentinel nodes was biopsied. The overall identification rate was 88%, accuracy was 92%, and false-negative rate was 22%. All rates were improved in younger (age <50 years) compared with older women. A positive lymphoscintiscan and the mapping agent used were associated with higher identification rates but not accuracy or false negative rates. Increasing surgeon experience was not significantly associated with improvements in identification or false-negative rates.

CONCLUSIONS

The potential of SNB was not fully translated into surgical practice in BC by 2001.